Prostate Cancer (Adenocarcinoma)

    Genetic Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    Androgen receptor 50 (mutation) (1)
    25–30 (amplification) (2)
    Abiraterone (17 alpha-hydroxylase/C17,20-lyase inhibitor) (FDA approved):
    • Phase 3, after chemotherapy: OS 14.8 vs. 10.9 mo with placebo, PSA RR 29% vs. 6%, ORR 14% vs. 3% (3)
    • Phase 3, before chemotherapy: PFS 16.5 vs. 8.3 mo with placebo, mOS not reached in abiraterone treatment group, PSA RR 62% vs. 24%, ORR 36% vs. 16% (4)
    Enzalutamide (androgen receptor antagonist) (FDA approved):
    • Phase 3, after chemotherapy: OS 18.4 vs. 13.6 mo with % (5)
    Other topics in Targets by Organ Site